Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL466420 | 0.87 | MEN1 (0.62) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL4581519 | 0.87 | LMNA (0.62) | MEN1LMNAKMT2AFFAR3LCK | |
| Tromethamine SCHEMBL7347818 | 0.87 | LMNA (0.62) | MEN1LMNAKMT2AFFAR3LCK | |
| Tromethamine SCHEMBL194002 | 0.87 | LMNA (0.62) | MEN1LMNAKMT2AFFAR3LCK | |
| Tromethamine SCHEMBL8530527 | 0.85 | MEN1 (0.59) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL8573552 | 0.85 | MEN1 (0.59) | MEN1LMNAKMT2A | |
| Acetic Acid SCHEMBL3431821 | 0.82 | FFAR3 (0.50) | LMNAFFAR3LCKFYN | |
| Acetic Acid SCHEMBL31396472 | 0.82 | — | — | |
| Tromethamine SCHEMBL5891164 | 0.80 | MEN1 (0.53) | MEN1LMNAKMT2AFFAR3LCK | |
| Tromethamine SCHEMBL3473649 | 0.80 | LMNA (0.53) | MEN1LMNAKMT2AFFAR3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0432221-B1 | ONE-STEP IN SITU HYBRIDIZATION ASSAY | APROGENEX INC (US) | 1997-05-28 | — | — | EP | claimed |
| US-9164099-B2 | Site-specific labeling of affinity tags in fusion proteins | Life Technologies Corporation (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140038856-A1 | Site-specific labeling of affinity tags in fusion proteins | Life Technologies Corporation (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120270757-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | Life Technologies Corporation (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2217608-B1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | BIO RAD LABORATORIES (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2217608-A1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | Bio-Rad Laboratories, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2089429-A2 | PROCESS FOR PREPARING UNAGGREGATED ANTIBODY FC DOMAINS | Centocor Ortho Biotech Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009067603-A1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | BIO-RAD LABORATORIES, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131640-A1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | BIO-RAD LABORATORIES, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090081722-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | INVITROGEN CORPORATION (US) | 2009-03-26 | — | — | US | disclosed |
| US-20060141554-A1 | Site-specific labeling of affinity tags in fusion proteins | INVITROGEN CORP. | 2006-06-29 | — | — | US | disclosed |
| US-20050233307-A1 | Site-specific labeling of affinity tags in fusion proteins | Life Technologies Corporation | 2005-10-20 | — | — | US | disclosed |
| WO-2005083394-A2 | METHODS FOR DETECTING ANIONIC AND NON-ANIONIC PROTEINS USING CARBOCYANINE DYES | MOLECULAR PROBES, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1546359-A2 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | Molecular Probes Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005038460-A2 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | MOLECULAR PROBES, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004025259-A2 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | MOLECULAR PROBES, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-6316267-B1 | COMBINING SAMPLE MIXTURE CONTAININGPOLY(AMINO ACID) WITH A STAINING MIXTURE THAT CONTAINS ONE OR MORE METAL COMPLEXES; INCUBATING COMBINED MIXTURE; ILLUMINATING SAID DYE-POLY(AMINO ACID) COMPLEX; OBSERVING DETECTABLE OPTICAL RESPONSE | MOLECULAR PROBES, INC. | 2001-11-13 | — | — | US | disclosed |
| EP-1042676-A1 | LUMINESCENT PROTEIN STAINS CONTAINING TRANSITION METAL COMPLEXES | Molecular Probes Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000025139-A1 | LUMINESCENT PROTEIN STAINS CONTAINING TRANSITION METAL COMPLEXES | MOLECULAR PROBES, INC. (US) | 2000-05-04 | — | — | WO | disclosed |
| US-4205130-A | AFFINITY VHROMATORGAPHY, ISOELECTRIC FOCUSING | VIHKO PIRKKO | 1980-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060141554-A1 | Site-specific labeling of affinity tags in fusion proteins | APBA1, F13A1, F13B | MEN1 320/4885LMNA 114/4885KMT2A 1830/4885 |
| US-20090131640-A1 | PHOTOLUMINESCENT METAL COMPLEXES FOR PROTEIN STAINING | NR2E3, NR2C2, ORC3 | MEN1 4674/4885LMNA 4298/4885KMT2A 3006/4885 |
| US-20120270757-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | APBA1, NAPA, F13B | MEN1 271/4885LMNA 115/4885KMT2A 1632/4885 |
| US-20090081722-A1 | SITE-SPECIFIC LABELING OF AFFINITY TAGS IN FUSION PROTEINS | APBA1, F13A1, F13B | MEN1 320/4885LMNA 114/4885KMT2A 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.